AD109 pill shows promise for Obstructive_sleep_apnea

A new once-nightly pill, AD 109>>>, developed by Apnimed>>>, has shown promising results in a large phase 3 clinical trial (SynAIRgy) for treating obstructive sleep apnea (OSA). The trial, conducted across 69 sites in the United States>>> and Canada>>> with 646 adults, demonstrated that AD 109>>> significantly reduced breathing interruptions and improved oxygen levels in patients who could not tolerate or refused Continuous positive airway pressure>>> (CPAP) machines. Over 40% of participants moved to a lower OSA severity category, and 18% achieved complete disease control. AD 109>>>, a combination of Oxybutynin>>> and Atomoxetine>>>, targets the underlying neuromuscular causes of airway collapse during sleep. The drug exhibited an acceptable safety profile with mild side effects. The United States — Food and Drug Administration>>> has granted AD 109>>> Fast Track designation, and Apnimed>>> has submitted a New Drug Application, with a decision anticipated in Q1 2027. Patrick John Strollo>>>, a sleep medicine physician at the University of Pittsburgh Medical Center, was the lead author of the study published in the American Journal of Respiratory and Critical Care Medicine>>>.